202: CE: New guidelines in the management of canine parvovirus

Sponsored by Elanco. Head to dvm360 Flex and login or create a free CE account and claim your credit after listening to this episode.Program Description: Canine Parvovirus (CPV) infection is one of the most common and serious infectious diseases of puppies and dogs younger than 6 months of age. We will discuss the diagnosis and differential diagnosis of CPV and emphasize expected laboratory changes including hematologic and electrolyte abnormalities. Exciting new treatments for CPV will be discussed including the Canine Parvovirus Monoclonal Antibody (CPMA) which is the first and only USDA-conditionally approved monoclonal antibody treatment that targets CPV. CPMA selectively binds and blocks canine parvovirus from entering and destroying the enterocytes stopping this destructive and potentially deadly virus. Program Agenda:  Overview of Canine Parvovirus (CPV)  Understanding how CPV impacts our patients, our clients and our hospital staff Reviewing the diagnosis of CPV and potential pitfalls Clinicopathologic changes and monitoring treatment of CPV Canine Parvovirus Monoclonal Antibody (CPMA)—a new and novel treatment for CPV Learning Objectives:  Develop a differential diagnostic list of diseases affecting puppies with common presenting signs of vomiting and /or diarrhea. List the expected hematologic changes expected in patients infected with CPV. Understand the rationale and protocol used in the treatment of CPV with canine parvoviral monoclonal antibody (CPMA).